Equities

Abcellera Biologics Inc

Abcellera Biologics Inc

Actions
  • Price (EUR)2.49
  • Today's Change-0.05 / -1.97%
  • Shares traded3.00k
  • 1 Year change-36.86%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments761886723
Total Receivables, Net64103175
Total Inventory1.111.531.67
Prepaid expenses219.065.29
Other current assets, total252525
Total current assets8721,025930
Property, plant & equipment, net288217112
Goodwill, net484848
Intangibles, net120132148
Long term investments987350
Note receivable - long term------
Other long term assets624631
Total assets1,4881,5411,319
LIABILITIES
Accounts payable------
Accrued expenses14123.65
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total8091102
Total current liabilities119118121
Total long term debt000
Total debt000
Deferred income tax313337
Minority interest------
Other liabilities, total186156135
Total liabilities336308293
SHAREHOLDERS EQUITY
Common stock753734722
Additional paid-in capital1217435
Retained earnings (accumulated deficit)280426268
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(1.72)(1.39)0.28
Total equity1,1521,2331,026
Total liabilities & shareholders' equity1,4881,5411,319
Total common shares outstanding291287283
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.